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Abstract: 
Modelling disease with hPSCs is hindered because the impact on cell 
phenotype from genetic variability between individuals can be greater than 
from the pathogenic mutation. While ‘footprint-free’ Cas9/CRISPR editing 
solves this issue, existing approaches are inefficient or lengthy. Here, a 
simplified PiggyBac strategy shortened hPSC editing by 2 weeks and 
required one round of clonal expansion and genotyping rather than two, 
with similar efficiencies to the longer conventional process. Success was 
shown across 4 cardiac-associated loci (ADRB2, GRK5, RYR2, ACTC1) by 
genomic cleavage and editing efficiencies of 8-93% and 8-67%, 
respectively, including mono- and/or bi-allelic events. Pluripotency was 
retained, as was differentiation into high purity cardiomyocytes (CMs; 88-
99%). Using the GRK5 isogenic lines as an exemplar, chronic stimulation 
with the b-adrenoceptor agonist, isoprenaline, reduced beat rate in hPSC-
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CMs expressing GRK5-Q41 but not GRK5-L41; this was reversed by the b-
blocker, propranolol. This simplified, footprint-free approach will be useful 
for mechanistic studies. 
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Abstract:  1 
Modelling disease with hPSCs is hindered because the impact on cell phenotype from genetic 2 
variability between individuals can be greater than from the pathogenic mutation. While ‘footprint-free’ 3 
Cas9/CRISPR editing solves this issue, existing approaches are inefficient or lengthy. Here, a simplified 4 
PiggyBac strategy shortened hPSC editing by 2 weeks and required one round of clonal expansion and 5 
genotyping rather than two, with similar efficiencies to the longer conventional process. Success was 6 
shown across 4 cardiac-associated loci (ADRB2, GRK5, RYR2, ACTC1) by genomic cleavage and editing 7 
efficiencies of 8-93% and 8-67%, respectively, including mono- and/or bi-allelic events. Pluripotency was 8 
retained, as was differentiation into high purity cardiomyocytes (CMs; 88-99%). Using the GRK5 isogenic 9 
lines as an exemplar, chronic stimulation with the β-adrenoceptor agonist, isoprenaline, reduced beat rate 10 
in hPSC-CMs expressing GRK5-Q41 but not GRK5-L41; this was reversed by the β-blocker, propranolol. This 11 
shortened, footprint-free approach will be useful for mechanistic studies. 12 
 13 
14 
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Introduction 1 
Human pluripotent stem cells (hPSCs) comprise both human embryonic stem cells (hESCs), derived 2 
from the inner cell mass of the preimplantation embryo, and human induced pluripotent stem cells (hiPSCs), 3 
derived by epigenetic reprogramming of somatic cells [1]. It is now well established that hPSCs are an 4 
important modality for biomedicine, with application ranging from understanding human development 5 
through to use of their differentiated progeny in safety assessment of drugs, accelerating drug use towards 6 
clinic and modelling genetic disease [1]. Suitability in several clinical trials has been, or is being evaluated, 7 
including for spinal cord injury, macular degeneration and heart disease [2]. A difficulty that has emerged 8 
for the in vitro assays is genetic variation between unrelated individuals may cause greater phenotypic 9 
differences than do the disease-associated polymorphism(s) [3]. Therefore, creation of isogenic pairs, 10 
wherein only the polymorphism of interest differs between lines, is now considered the gold standard. 11 
While the number of reports using conventional gene targeting in hPSC is low, the advent of nuclease-12 
mediated targeting, particularly with Cas9/CRISPR, has made precise modification of the genome relatively 13 
routine [1].  14 
Despite these advances, difficulties still remain in gene editing of hPSCs. Making single base pair 15 
substitutions is technologically challenging when compared to, for example, gene knockouts, where 16 
libraries of guide RNAs (gRNAs) are being used in functional genome-wide screens [4]. An important 17 
consideration for editing is that, other than the desired polymorphic changes, the level of genome 18 
modification post-gene edited hPSC line should be minimal. This is because residual footprints left behind 19 
after targeting can alter or abolish neighbouring gene expression [1,5,6]. This advocates the use of 20 
footprint-free or scarless approaches.  21 
One route to achieving footprint-free editing is via the delivery of ribonucleoprotein combinations 22 
that comprise recombinant Cas9 protein, in vitro transcribed gRNA and a ~50-150 base single-stranded DNA 23 
oligonucleotide (ssODN) template, which carries the polymorphic change(s) of interest [7]. We 24 
demonstrated the utility of this approach by modifying the ADRB2 locus, which encodes the β2-25 
adrenocetor [1], while others have altered additional loci [7,8]. Although this route is attractive and less 26 
toxic than plasmid approach [7], it requires high transfection rates of large complexes, which can be 27 
difficult in sensitive cells such as hPSCs. The lack of a drug selection marker also that means considerable 28 
screening effort is needed to identify positive clones. An alternative to achieving seamless editing by using 29 
ssODNs as a template is via a system termed “CORRECT” [9]; however, this requires two sequential clonal 30 
selection/expansion steps.  31 
An alternative for footprint-free editing is the PiggyBac transposon system [10], although this does 32 
require a TTAA quadra-nucleotide site for recombination (see Fig. 1). In this approach, a targeting vector 33 
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contains a positive-negative drug selection cassette (e.g. Puro-∆TK; Fig. 1A) that is flanked by PiggyBac 1 
recombination sites. In turn, these components are flanked by regions of up to 1kb in length that are 2 
homologous to the endogenous target locus, thus enabling recombination between template and genome. 3 
The desired polymorphism(s) is carried within one arm of homology. Experimentally, the approach is 4 
implemented via two sequential steps. First, the targeting vector is co-transfected with plasmids carrying 5 
guide RNA and Cas9 to promote genomic cleavage and insertion via homology directed repair into the locus 6 
of interest. Survival during positive selection with antibiotics (e.g. puromycin) identifies the hPSC clones 7 
that express the cassette, which are then picked, expanded and genotyped (Fig. 1B). Second, antibiotic 8 
resistant hPSCs are transfected with a plasmid expressing transposase, which induces internal 9 
recombination between PiggyBac sites, excision of the selection cassette and reconstitution of a footprint-10 
free locus (Fig. 1B). Colonies that fail to excise the cassette continue to express ∆TK and hence are 11 
negatively selected against by the prodrugs, ganciclovir or fialuridin. This leaves the surviving colonies, 12 
which can be picked, expanded and genotyped for a second time.  13 
Several reports have described the successful use of this PiggyBac approach in hPSC [11,12,13]. 14 
Nevertheless, the requirement for two rounds of clonal selection and genotyping over a lengthy timeline is 15 
problematic. Particularly for hPSCs, the number of cumulative population doublings correlates genetic [14] 16 
and epigenetic [15,16] instability, thereby affecting their downstream applications [17]. Similarly, in mouse 17 
iPSCs, genetic instability has been reported within as few as 4-6 passages [18]. Thus, processes that enable 18 
gene editing in shorter timelines would be beneficial [19]. 19 
In this report we adapted a footprint-free PiggyBac-based Cas9/CRISPR gene editing strategy to 20 
both simplify and shorten the process. Only one round of clonal selection and genotyping is needed, 21 
reducing the process from 49 to 35 days, a 25-30% time saving that equates to ~14 population doublings in 22 
hPSCs. We have demonstrated the utility of this simplified approach by making single or dual polymorphic 23 
changes to 4 cardiac-related genes, ADRB2, GRK5, RYR2 and ACTC1. For each of the engineered hPSC lines 24 
created, we showed that the cells retained expression of pluripotency markers, a stable karyotype and the 25 
ability to differentiate at high efficiency into beating cardiomyocytes that express α-actinin. As an exemplar, 26 
we showed significant differences in functional consequence between isogenic pairs of hiPSC-CMs that 27 
carry GRK5-L41 or GRK5-Q41 polymorphisms in response to chronic β-adrenergic stimulation and β-blocker 28 
rescue. Thus, the approach described provides a simplified and abbreviated route towards mechanistic 29 
understanding of how single polymorphic variants alter heart function.  30 
 31 
32 
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Materials and Methods 1 
 2 
Cell culture 3 
All culture was at 37
o
C at 5% CO2 in a humidified atmosphere. Unless otherwise stated, all reagents 4 
were from ThermoFisher. HUES7 hESCs were gifted by Chad Cowan and Doug Melton at the Harvard Stem 5 
Cell Institute. Fibroblasts were derived under ethical consent from individual with the genotypes RYR2
6739C/T
 6 
(NRES Committee East Midlands – Nottingham 2 approval 09/H0408/74) and ACTC1
301G/G
 (Biomedical 7 
Institute of A Coruna, INIBIC). Reprogramming to hiPSCs was via CytoTune 2.0 (ThermoFisher), according to 8 
the manufacturer’s instructions. Culture was in E8 medium on Matrigel, although processes could also be 9 
completed in hESC medium conditioned using mouse embryonic fibroblasts [20]. In the first 4-5 passages 10 
after reprogramming, cell harvesting was done using 0.5mM EDTA and thereafter with accutase. 11 
 12 
Transfection Optimisation 13 
For transfection and electroporation experiments, hPSCs were seeded at 3x10
5
 cells/well of the 14 
Matrigel-coated 6 well plate or resuspended cells at 2x10
5
 cell/well/transfection condition in Nucleocuvette 15 
Strip (16 wells), respectively. Plasmids were transfected into hPSCs using either FuGene HD transfection 16 
reagent (Promega, E2311) following the manufacturer’s instructions using a ratio between reagent and 17 
plasmid DNA of 4:1. To optimise the electroporation using the Amaxa 4D system (Lonza), pmaxGFP plasmid 18 
provided in the Lonza Amaxa 4D kit was transfected into hPSCs with human stem cell P3 solution (programs: 19 
CA-137, CB-150, CD-1118, CE-118, CM-113, DC-100, DN-100, as recommended by the manufacturer’s 20 
protocol). The GFP signal was captured using Operetta High-content imaging system (Perkin Elmer) and 21 
analysed using Harmony High-content imaging software.  22 
 23 
Targeting vector construction 24 
The ADRB2 targeting vector was constructed via Gibson assembly by using Gibson Assembly master 25 
mix (E2611S NEB). Overlapping fragments were produced by PCR (GoTag polymerase, Promega) for three 26 
inserts: Dual drug selection cassette (Puro-∆TK) flanked by PiggyBac recombination sites; and the left and 27 
right homology regions for ADRB2 (~1kb upstream and ~1kb downstream of the locus cut site). Primers 28 
used are shown in Supplementary Table 1. An EcoRV digested pBluescript backbone plasmid sequence was 29 
used as the fourth DNA fragment in the Gibson assembly. A 20µl reaction containing 0.24 pmol of each 30 
insert, 0.08pM of Bluescript backbone and 1X Gibson Assembly® Master Mix (NEB) was heated at 50°C for 31 
60 minutes. Subsequent transformation into Top10 competent cells and colony sequencing identified 32 
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correctly assembled plasmids.  The same approach was used to generate the GRK5, ACTC1 and RYR2 1 
targeting constructs.  2 
 3 
Gene targeting in hPSCs 4 
FuGene HD (Promega) transfection required seeding of 3x10
5
 hPSCs into each well of a Matrigel-5 
coated 6-well plate. Twenty-four hours later, cells were transfected 3.3 μg of CRISPR plasmid components 6 
(targeting plasmid, gRNA, Cas9). For Amaxa 4D nucleofection (Lonza), 3x10
6
 hPSCs and 3 μg of CRISPR 7 
plasmid components were used with P3 solution, program CA-137. Transfected and nucleofected cells were 8 
maintained in E8 medium on Matrigel (hESC medium conditioned using mouse embryonic fibroblasts [20] 9 
could also be used). Twenty-four hours post-transfection, medium was supplemented with puromycin (0.25 10 
to 7.5 μg/mL; cell line dependent) for positive selection of clones up to two weeks. The puromycin-positive 11 
clones were then harvested and expanded as described in the cell culture section. For cassette excision, 12 
cells were seeded at 3x10
5
 cells/well of a Matrigel-coated 6-well plate before delivering transposase 13 
plasmid by transfection (3 μg) using FuGene HD transfection as described above. Cells were reseeded to 10 14 
cm dishes, incubated for 2-3 days to allow recombination by transposase and then exposed to medium 15 
containing ganciclovir (2 μg/mL) for negative selection of PiggyBac excision. Approximately 7-10 days later, 16 
clones were manually dissected and genotyped using primers shown in Supplementary Table 1. See this 17 
Table and also Figure 3 for location of primers to test for off-target and random integration events. 18 
Realtime qPCR to the ampicillin gene was conducted by GoTag® qPCR Master mix (Promega, #A6001) on 19 
Applied Biosystems SDS 7500 Fast Real-time PCR template f r 45 cycles. Melting curves was obtained for all 20 
experimental runs. Relative expression of genes was calculated and expressed as 2−ΔΔCt, normalised using 21 
18S. 22 
 23 
Characterisation of hPSC 24 
A) Cardiomyocyte differentiation: 25 
Undifferentiated hPSCs were seeded onto Matrigel-coated dishes at a density of 4x10
4
 cells/cm
2
 and 26 
allowed to expand for 48h (~80% confluency). At this stage (d1 of differentiation), cultures were treated 27 
with medium comprising StemPro34 supplemented with [1:100 dilution) Matrigel and [1 ng/ml] BMP4 28 
(R&D systems). After 24h (d2 of differentiation), medium comprising StemPro34 with [10 ng/ml] BMP4 and 29 
[8ng/ml] Activin A (Life Technologies). Medium exchange was performed on d4 of differentiation using 30 
RPMI supplemented with 1xB27 (Life Technologies) and small molecule inhibitors, KY02111 (10 μM) and 31 
XAV939 (10 μM) (R&D systems). From d8 onwards, cells were maintained in RPMI medium supplemented 32 
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with B27 only, with medium changes every 3 days. Cardiac differentiation efficiency was accessed by using 1 
immunocytochemistry with primary mouse anti-human α-actinin antibody (Sigma #A7811, 1:800) dilution; 2 
secondary goat anti-rabbit Alexa633 (Invitrogen #A21052, 1:400); counterstaining with 0.5 μg/ml DAPI 3 
(Sigma #D9542, 1:500). Immunofluorescence images were captured using Operetta High-content system 4 
(Perkin Elmer) and analysed using Harmony high-content analysis software. 5 
 6 
B) Gene exp ession: 7 
RNA was isolated from undifferentiated hPSCs and derived cardiomyocytes at day 14 of 8 
differentiation using RNeasy mini kit (Qiagen). Synthesis of cDNA was carried out using 1 µg RNA with 9 
SuperScript III Reverse Transcriptase kit (Invitrogen), according to manufacturer instructions. ADRB2 10 
analysis was with Taqman qPCR (Applied Biosystems, #Hs00240532_s1) and signals were normalised to 11 
GAPDH (Applied Biosystems, #Hs99999905_m1) as the housekeeping gene, following the manufacturer’s 12 
instructions. Semi-quantitative PCR cycle conditions were 95
o
C for 2 min, 64.5
o
C for 30 sec (GRK5, ACTC1, 13 
RYR2 and ACTB) and 72
o
C for 60 sec, with a final elongation step of 72
o
C for 10 min. Each reaction used 250 14 
ng of cDNA with Phusion polymerase (NEB) for 35 cycles. Gels were imaged with a LAS-4000 (Fujifilm) 15 
image analyser, densitometry was carried out using FIJI, a version of ImageJ (National Institutes of Health) 16 
and signals were normalised to ACTB as the housekeeping gene. Primers for expression analysis are 17 
provided in Supplementary Table 1.  18 
 19 
C) Immunocytochemistry analysis of nuclear pluripotent markers: 20 
Human PSCs were cultured at 30,000 cells/cm
2
 in Matrigel-coated 96-well plates (Perkin Elmer 21 
CellCarrier) until reaching 60% confluent before fixing with 4% PFA. Fixed cells were perforated using 0.01% 22 
Triton X-100 and 0.05% Tween 20 (diluted in PBS). The cells were then incubated with mouse-anti human 23 
OCT4 (C-10 clone, Santa Cruz Biotech #sc-5279, 1:100) and subsequent secondary antibody using goat-anti 24 
mouse Alexa488 (Invitrogen #A11001, 1:1000), counterstained with 0.5 μg/ml DAPI. Immunofluorescence 25 
images were captured using Operetta High-content system (Perkin Elmer) and analysed using Harmony 26 
high-content analysis software. 27 
 28 
D) Flow cytometry analysis of surface pluripotent markers 29 
To analyse surface markers, hPSCs were harvested and fixed using 4% PFA followed by incubation 30 
with PE-conjugated SSEA-1 (eBioMC-480 clone, ThermoFisher #12-4752, 1:100), SSEA-4 (eBioMC-813-70 31 
clone, ThermoFisher #12-8843, 1:200) and TRA-1-81 (TRA-1-81 clone, ThermoFisher #12-8883, 1:100) 32 
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antibodies for 20 min at 4
o
C. Cells were analysed using an FC500 Flow cytometer (Beckman Coulter) and 1 
data were analysed with FlowJo software. 2 
 3 
E) Karyotyping: Metaphase spreads were prepared as previously described [20] from hPSCs after final 4 
genotype was confirmed, and karyotype analysis was performed by G-banding of 30 metaphase spreads in 5 
each sample, according to guidelines from the International System for Human Cytogenetic Nomenclature.  6 
 7 
Functional analysis of GRK5 hPSC-cardiomyocyte polymorphic variants 8 
To measure the beat rate of CMs in real time, the CardioExcyte96 system (Nanion) was used. Briefly, 9 
the 96-well sensor plates of the CardioExcyte96 were coated by incubation (1.5 h) with fibronectin at 1:100 10 
dilution in PBS (without Ca
2+
 and Mg
2+
). CMs at d25 to d28 were dissociated and seeded onto the sensor 11 
plate at 60,000 cells/well. Plates were incubated for 48h before changing the medium and starting the 12 
recordings according to the following timeline: 0-2 h, baseline recording; 2 h, spike with 100nM 13 
isoprenaline; 24 h, repeat spike of isoprenaline; 48-50 h, end of recording. Beat rate of CMs was recorded 14 
throughout the experiments at intervals of 2 to 10 minutes. For the non-selective beta-blocker experiment, 15 
propranolol (200 nM) was added 1 hour before starting isoprenaline treatment and maintained throughout. 16 
 17 
 18 
Results 19 
 20 
Locus selection and targeting strategy for ADRB2 (β2-adrenoceptor) 21 
Over the course of multiple experiments in our laboratory, we observed Cas9/CRISPR gene 22 
targeting efficiencies of ~30% (158 of 421 colonies assessed) across 12 different loci and/or hPSC lines (data 23 
not shown) when using optimised transfection conditions (Supp. Fig. 1). In the context of the 2 step 24 
PiggyBac process, we reasoned that the gene targeting efficiency during step 1 would be rate limiting 25 
because cassette excision should occur in most cells, provided transposase delivery is at high efficiency at 26 
the start of step 2. An alternative strategy could be to merge steps 1 and 2 of the PiggyBac process. This 27 
would have the advantage of not only simplifying editing, but also of reducing the time to produce gene 28 
modified hPSCs by 14 days; this equates to ~14 population doublings and 25-30% of the whole targeting 29 
process (Fig. 1B).  30 
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To test this notion, we selected the ADRB2 locus for several reasons. ADRB2 encodes β2-1 
adrenoceptor, a G-protein coupled receptor that has an N-terminal domain positioned in the extracellular 2 
compartment. In this domain, two polymorphic variants at amino acid positions p.Gly16Arg (c.G46A) and 3 
p.Glu27Gln (c.G79C) alter patient response during heart failure [21]. Thus, production of isogenic hPSC lines 4 
from which cardiomyocytes can be produced would be beneficial in understanding the mechanism of these 5 
differences. We also selected this locus because it is expressed in undifferentiated hPSCs, albeit at much 6 
lower levels than in hPSC-cardiomyocytes (Fig. 1C). This may be useful since an ‘open’ configuration is 7 
considered to be more permissible to gene targeting [22]. However, ADRB2 also requires a footprint-free 8 
strategy because it is a single exon gene with complex 5’ and 3’ untranslated regions, which include 9 
multiple regulatory elements and domains required for proper expression of ADRB2 and its membrane 10 
targeting [23,24,25]. As such, positioning a selection cassette or a short footprint in these regions may be 11 
disruptive to cell signalling and function, even in the undifferentiated state. 12 
The PiggyBac approach requires an endogenous quadra-nucleotide TTAA palindrome sequence at 13 
the site of recombination, which theoretically occurs at 329bp intervals through the genome [26]. However, 14 
the PiggyBac transposon has a preference for areas surrounding transcription start sites and CpG islands [27], 15 
suggesting that even distribution of TTAA sites does not occur. Supporting this notion, our analysis of the 16 
genomic regions flanking the position 46 or 79 ADRB2 polymorphic variants in HUES7 hESCs revealed that 17 
the nearest TTAA site was 748 bases away (data not shown), which far exceeds the distance recommended 18 
for insertion via nuclease-mediated targeting [10]. However, we noted the sequence CTC ATC (nucleotide 19 
position 124-129) situated 45 bases downstream of the position 79 polymorphism in ADRB2 coding 20 
sequence; codon redundancy for leucine meant that substitutions could be made to TTA ATC, which 21 
created the TTAA site necessary for PiggyBac recombination whilst being synonymous and retaining the 22 
native Leu41-Ile42 peptide sequence (Fig. 2). We sought to minimise any further changes, silent or 23 
otherwise, to the ADRB2 locus. Therefore we selected a gRNA with a protospacer adjacent motif (PAM) 24 
overlapping the polymorphic change c.G79C, ensuring cleavage of genomic, but not targeting vector, 25 
sequences would occur (Fig. 2; Supp Table 1). Thus, the left arm of homology in the targeting vector 26 
contained c.G46A (p.Gly16Arg), c.G79C (p.Glu27Gln) and c.C124T/c.C126A (synonymous: p.Leu41-Ile42) 27 
modifications directed towards the ADRB2 locus (Fig. 1A; Fig. 2).  28 
 29 
Simplified PiggyBac gene editing in ADRB2 in hPSCs 30 
The process outlined in Fig. 1 entails 2 steps, with gene targeted insertion of the PiggyBac cassette 31 
and the associated polymorphic changes occurring in the first step, followed by transposase-mediated 32 
cassette removal in the second step. Since we anticipated cassette excision should occur at high efficiency 33 
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(Supp Fig. 1), we wished to test whether the frequency and types of targeting events was similar after first 1 
(midpoint) and second (end) steps. In addition, we wanted to ensure that streamlining the process by 2 
progressing directly from positive (puromycin) to negative (ganciclovir) selection did not have a detrimental 3 
effect.  4 
HUES7 hESCs were co-transfected with Cas9, gRNA and ADRB2 targeting plasmids, and then 5 
subjected to puromycin treatment. Once early stage drug resistant colonies had formed, a portion of the 6 
colonies were picked for genotyping after step 1. The remainder of the cells were harvested, transfected 7 
with transposase and then treated with ganciclovir, before allowing colonies to form for picking and 8 
genotyping after step 2. All clones were assessed by PCR amplification coupled to direct sequencing across 9 
the left arm of homology (Fig. 3A; Supp Table 1; Supp. Fig. 2A,B). Genotyping after first vs second step 10 
showed high frequencies (Fig. 3B), wherein genomic cleavage was evident in 8/11 (73%) and 6/12 (50%). 11 
Specifically between categories 18% vs 8% untargeted, 9% vs 8% mono-allelic targeting, 9% vs 33% bi-allelic 12 
targeting, 55% vs 8% indels, indicated by messy reads around Cas9 cleavage site, and 9% vs 42% unclear 13 
result, indicated by PCR failure or lack of sequencing data (Fig. 3A; Supp. Fig 2A,B).  14 
We also evaluated off target events (Fig. 3C; Supp Table 1). We focussed on known coding or 15 
regulatory sequences where gRNAs had full PAM site complementarity and/or fewer than 5 mismatches 16 
with the target. The 5 putative sites that met these criteria were shown by PCR amplification and 17 
sequencing to be unaffected by off targeting (Fig. 3C). Therefore, the simplified PiggyBac approach was 18 
successfully used to produce an isogenic set of wildtype (untargeted), heterozygote (mono-allelic) and 19 
homozygote (bi-allelic) dual-site modifications at nucleotide positions 46 and 79 in the 5’ end of the ADRB2 20 
gene in hESCs.    21 
Finally, we tested for unwanted random integration events of the vector elsewhere in the genome 22 
by PCR (Fig. 3D). As expected, control primers that spanned the PAM site in ADRB2 gave a product from 23 
parental cells and after step 2, but not step 1 since the bi-allelic presence of a complex puro-∆TK cassette 24 
blocks the PCR reaction. Correspondingly, PCR products specific to the ADRB2-puro-∆TK junction and to 25 
∆TK were produced only from step 1 samples, indicating that no residual targeting selection cassette could 26 
be detected after transposase-mediated removal. Remnants of the pBlueScript plasmids backbone were 27 
tested for by PCR to the ampicillin gene. No products were seen by conventional PCR (data not shown). 28 
Therefore, qPCR was carried out using a positive control, wherein targeting plasmid DNA was diluted to the 29 
equivalent of a single genomic copy into parental HUES7 DNA. Relative to this positive control, samples 30 
from parental cells, step 1 and step 2 gave a signal 10- to 20-fold lower. Collectively, these data suggest 31 
that precise targeting of the selection cassette occurred only at the ADRB2 locus and not at random 32 
elsewhere in the genome, and cassette excision occurs after transposase-mediated removal.  33 
Page 11 of 39
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
Stem Cells and Development
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only/Not for Distribution
11 
 
 1 
Applying simplified PiggyBac gene editing to other cardiac-associated loci in hPSCs 2 
 Efficiency of gene targeting, including using Cas9/CRISPR, is known to be influenced by genomic 3 
environment, including complexity and GC-richness of gene sequence, active gene expression, availability 4 
of sites to guide nuclease docking, and cell type. Therefore, we selected 3 additional cardiac-associated loci 5 
with diff rent genetic properties but each with relevance to human health or heart disease (Fig. 4).  6 
GRK5 encodes GPCR specific kinase involved in β-adrenergic receptor desensitisation. It has been 7 
suggested that a c.A122T (p.Gln41Leu) polymorphism causes a natural β-blocker effect that may be 8 
protective against heart disease [28]. ACTC1 encodes cardiac actin and a mutation at c.G301A (p.Glu101Lys) 9 
causes hypertrophic cardiomyopathy, altered calcium sensitivity, arrhythmias and, in some cases, sudden 10 
cardiac death [29]. Finally, RYR2 encodes ryanodine receptor, which is a calcium release channel in the 11 
sarcoplasmic reticulum. A highly malignant mutation of c.C6737T (p.Ser2246Leu) causes catecholaminergic 12 
polymorphic ventricular tachycardia (CPVT), which can lead to sudden cardiac death [30].  13 
All 4 genes were expressed in undifferentiated hPSCs (Figs 1 & 5), which is surprising since ACTC1 14 
encodes for cardiac actin, a cardiomyocyte specific structural protein (Fig. 5). The GC content of the region 15 
surrounding the polymorphisms, gRNA and TTAA sites differs between ADRB2 (64%), GRK5 (56%), ACTC1 16 
(53%) and RYR2 (42%) (Figs. 2 & 5). Thus, this set provided an opportunity to test the simplified PiggyBac 17 
approach in genes differing in sequence composition and that were expressed at relatively low levels in 18 
hPSCs. 19 
Each gene was targeted in a different hPSC line out of necessity. The starting genotypes were hESC 20 
(line HUES7) GRK5
122A/A
, hiPSC ACTC1
301G/G
 from a healthy individual within a family with familial 21 
hypertrophic cardiomyopathy and hiPSC RYR2
6737C/T
 from a young patient with CPVT. In designing the 22 
targeting strategies (Fig. 5), we elected to use endogenous TTAA sites for PiggyBac recombination that 23 
resided in neighbouring introns. In addition, for each of the three genes (GRK5, ACTC1 and RYR2), gRNAs 24 
were chosen that spanned these TTAA sites; this means that the gRNAs recognised the endogenous 25 
genomic sequence but not the targeting vector because the TTAA demarcates the PiggyBac cassette 26 
insertion site (Fig. 5).  27 
Adopting these two strategies allowed production of true isogenic lines; i.e. no further sequence 28 
changes with potentially unknown effects were required either to form a de novo TTAA site or to protect 29 
the targeting vector from gRNA/Cas9 cleavage. The potential disadvantage of this approach is that the 30 
distance between gRNA/Cas9 cleavage site and the desired polymorphic change is increased, which raises 31 
the likelihood of recombination occurring between these two locations and hence not carrying the 32 
polymorphic change into the genome. Indeed, while the distance between PAM site and polymorphic 33 
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change was 107bp and 136bp for GRK5
122A/A
 and RYR2
6737C/T
 respectively, it was 313bp for ACTC1
301G/G
 (Fig. 1 
4).  2 
Targeting vectors were constructed for these genes (Figs. 4 & 5A) using the same design principles 3 
that were used for ADRB2 and thus relied on ~2kb of total homology, with ~1kb in each of the left and right 4 
arms (Fig. 1). Following positive (puromycin) and then negative (ganciclovir) selection, colonies were 5 
expanded for PCR and sequence analysis (Fig. 5C). For all three genes, successful targeting of the 6 
polymorphisms to the left arms was observed with concurrent excision of the PiggyBac selection cassette 7 
and reconstitution of the endogenous TTAA site (Fig. 5C,D). However, the targeting efficiencies differed 8 
considerably (Fig. 5D). In GRK5, genomic cleavage was confirmed in 93% clones, of which 13% and 47% 9 
were mono-allelic and bi-allelic targeting events respectively. This overall trend of correct targeting was 10 
similar to ACTC1, where cleavage was 75%, although this led to 67% and 0% mono-allelic and bi-allelic 11 
targeting events, respectively. In contrast, cleavage was only evident in 8% of RYR2 clones, which converted 12 
to a successful editing event. In summary, the simplified approach was used to produce footprint-free, 13 
isogenic pairs for 4 cardiac-related genes in hPSCs. 14 
 15 
Characterisation of gene edited hPSCs 16 
 Although correct targeting had been achieved, it was important to confirm whether specific 17 
pluripotency and differentiation characteristics were retained in ADRB2, GRK5, ACTC1 and RYR2 gene 18 
edited hPSC lines. Representative examples are shown (Fig. 6) but similar results were obtained from 19 
multiple clones, with the exception of RYR2 where only one successful targeting event was identified. In all 20 
cases, immunostaining coupled with high content image analysis showed that almost all cells expressed the 21 
pluripotency marker, OCT4. This was supported by flow cytometry, where 78-99% and 76-100% of hPSCs 22 
being positive for TRA-1-81 and SSEA4, whereas <3% displayed the differentiation marker, SSEA1 (Figure 6).  23 
The metaphase spreads of 30 cells per line were assessed by G-banding karyotyping. Assembly of 24 
homologous chromosomes into a karyogram showed no evidence of aberration. Finally, directed 25 
monolayer differentiation was used on each line to induce beating sheets of cardiomyocytes. These were 26 
dispersed on day 12-15 of differentiation and stained with α-actinin, before using high content image 27 
analysis to show cardiomyocyte purity was between 88 and 98%. Thus, the edited lines retained key 28 
characteristics of pluripotency, most notably differentiation to functional cardiomyocytes.  29 
 30 
Evaluating consequences of GRK5-L41 and –Q41 variants on hPSC-CM function 31 
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To demonstrate the utility of isogenic sets of hPSC lines, we selected wild type GRK5
122A/A
 and 1 
homozygote edited GRK5
122T/T
 lines, which differ only in leucine (L) or glutamine (Q) at position 41 of the 2 
encoded peptide. It has been suggested that the GRK5-L41 variant acts as a natural β-blocker and so is 3 
protective against adrenergic stress in the heart [28]. Therefore, we seeded confluent monolayers of 4 
cardiomyocytes derived from the GRK5 isogenic lines onto the CardioExcyte-96 impedance platform to 5 
assess beating characteristics during chronic (up to 50 hours) stimulation with the β-adrenoceptor agonist, 6 
isoprenaline (Fig. 7).  7 
During the first 30 hours of isoprenaline treatment, cardiomyocytes from both variants showed 8 
similar responses with maximum beat rates reaching ~150% of baseline values (Fig. 7Ai, Aii). This similarity 9 
was confirmed by calculating normalised beat rate (GRK5-Q41 divided by GRK5-L41), which gave values of 10 
close to 1 (Aiii). However, from 30 hours onwards, the normalised rate of GRK5-Q41 declined, finally 11 
reaching 60-80% of baseline by the 38-48 time window. In contrast, by the end of the evaluation period, 12 
GRK5-L41 maintained an average rate of 150%, which was reflected in a Q41/L41 response ratio of ~0.5 13 
(note arrows in Fig. 7Ai, ii, iii). This mirrors in vivo findings, which show that, unless compensation 14 
mechanisms can be invoked, prolonged (>30h) activation of adrenoceptors by catecholamines 15 
compromises cardiomyocyte recovery [28]. 16 
Since the GRK5-L41 variant has been suggested to impart a mild protective effect during chronic β-17 
adrenergic stimulation, we re-ran the experiment but this time with co-incubation of isoprenaline and the 18 
non-specific β-blocker, propranolol (Fig. 7B). As expected, the initial chronotropic response of both variants 19 
was subdued by propranolol. Notably, however, the chronic decline in beat rate to well below baseline 20 
levels seen by 38-48 hours in GRK5-Q41 with isoprenaline alone (Fig/. 7Bi) was abolished with the addition 21 
of propranolol (Fig. 7Bii) and was reflected by response rate ratios of close to 1 throughout the timecourse 22 
(Fig. 7Biii). Thus, chronic overstimulation of the β-adrenoceptor system eventually caused a decline in beat 23 
rate in GRK5-Q41, but not GRK5-L41 hPSC-CMs, and this could be reversed by β-blockade. This provides a 24 
tool for mechanistic understanding of genotype-phenotype interactions, which we are now investigating. 25 
 26 
Discussion 27 
We successfully demonstrated a simplified footprint-free approach to gene edit 4 distinct cardiac-28 
associated loci in hPSCs, with modifications including mono- and/or bi-allelic targeting. This included 29 
introducing polymorphic changes in hESC and/or hiPSC lines that were anticipated to be mildly beneficial to 30 
cardiomyocyte function into ADRB2 and GRK5 or severely damaging into ACTC1. We also corrected a 31 
damaging mutation in the RYR2 gene. The edited hPSC lines retained the ability to undergo high efficiency 32 
differentiation to cardiomyocytes, enabling us to demonstrate the utility of this approach by showing 33 
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functional differences in drug response for the GRK5 isogenic set. This simplified PiggyBac approach is 1 
easily adaptable to other loci, providing there is appropriate proximity of TTAA sites, either native or 2 
modified by engineering. Applicability will be irrespective of whether the targeting strategy employs 3 
conventional or nuclease (e.g. zinc fingers, TALE, Cas9/CRISPR) strategies and will be of future value in 4 
facilitating mechanistic studies.  5 
The need for isogenic hPSC lines was highlighted recently by Sala et al., 2016 [3]. Comparison of 6 
action potential duration 90 (APD90), an electrophysiology parameter, in cardiomyocytes derived from 18 7 
hPSC lines showed more than a 4-fold difference, with values ranging from ~140ms to 600ms. Even 8 
between different commercial suppliers of hPSC-cardiomyocytes, where quality control is high before 9 
release to customers, the range was 225ms to 600ms. A notable departure from this variation was one 10 
isogenic pair, where cardiomyocytes from both lines had highly similar APD90 values of ~230ms.  11 
Contextually, the normal range for humans APD90 values (usually cited as QT interval) is 350-450ms 12 
and increases of 10-20% are worrisome. During drug development such prolongation would likely lead to 13 
the termination the drug [31]. Clinically, QT intervals of >460-500ms usually signify disease state, such as 14 
long QT syndrome, which is caused by mutations in various ion channel proteins and can lead to sudden 15 
cardiac death [32]. This means that depending on the hPSCs selected, the phenotypic variation between 16 
lines (up to 400%) can be greater than any change caused by the mutation (usually 10 to 100%). This may 17 
explain some of the discrepancies reported in the literature for hPSC-based disease modelling, including for 18 
the magnitude of change caused by mutations in KNCQ1, which underlies long QT syndrome type 1 [33,34]. 19 
Consequently, the use of isogenic pairs is becoming the gold standard for disease modelling using hPSCs. 20 
The isogenic approach allows desired polymorphisms to be studied within the same genetic background 21 
and the ‘noise’ is eliminated from the other estimated ~11 million SNPs, 2.8 million short indels and 22 
~500,000 block substitutions that exist between unrelated individuals [35]. 23 
 A true isogenic pair will differ only in the desired polymorphic change. Part or whole remnants of 24 
selection cassettes can perturb gene function [36], even when positioned in introns because of the 25 
presence of currently unannotated sequences. Indeed, in hPSCs, we found that even when Cas9/CRISPR 26 
was used to target Ef1α-driven blasticidin or puromycin resistance markers into neighbouring introns, this 27 
abolished expression of KCNH2 [1] and MYH7 (Supp Fig. 3C) genes, which encode the HERG potassium ion 28 
channel and beta myosin heavy chain structural protein, respectively. In both cases cassette removal 29 
restored expression of KCNH2 and MYH7. For ADRB2, the complexity of the locus and absence of a nearby 30 
TTAA site necessitated conversion of CTC ATC to TTA ATC. In humans, both CTC and TTA are compatible 31 
with the leucine tRNA machinery but the probability of use is 0.2 and 0.07, meaning that CTC is preferred. 32 
Also, current gene annotation shows this change should not interfere with control regions (promoters, 33 
enhancers, non-coding RNAs, splice sites etc) but needs to be borne in mind during targeting design. Thus, 34 
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any changes, from single bases through to residual sequences ([1,37,38]; Supp Fig. 3) may need thorough 1 
investigation to rule out any potential negative impact on cell function. 2 
For loci that are more refractory to targeting, cultures can be pooled at the midpoint of the process 3 
(after step 1 / puromycin treatment) and an aliquot of cells taken for bulk PCR analysis. Primers are chosen 4 
to span from the selection cassette to the flanking genomic region of the locus of interest. If no PCR 5 
product is produced this may suggest the experiment should be abandoned. However, if there is a product 6 
then the cells can be re-seeded, transfected with transposase and then treated with ganciclovir to finish the 7 
excision / colony selection process.  8 
A surprising observation was that when cells at this puromycin resistant midpoint were 9 
cryopreserved, the positive-negative selection cassette was silenced upon thawing of the cells; this 10 
occurred across several loci beyond those described in this report. We are unsure as to why the 11 
cryopreservation-thaw cycle caused this effect. Indeed, it is well documented that silencing of transgenes 12 
occurs readily in hPSCs, particularly when non-mammalian promoters are used [39]. However, we used the 13 
mammalian promoter, phosphoglycerate kinase (PGK), which is usually well-tolerated [40,41]. We are not 14 
aware of other reports where transgene expression is maintained during long-term culture unless a 15 
cryopreservation-thaw cycle is introduced.  16 
Although all loci were targeted successfully, there were notable differences. Genome editing 17 
occurred at an efficiency of 42-67% in ADRB2, GRK5 and ACTC1, but only 8% in RYR2. All the genes were 18 
expressed but this is not a prerequisite for Cas9/CRISPR targeting. Our data for MYH7 showed a frequency 19 
of mono- and bi-allelic events totalled ~25% (Supp Fig. 3). In terms of GC content, RYR2 had the lowest 20 
(42%) around the target site, which might be expected to give better access for gene targeting rather than 21 
the lowly 8% reported here. This may be because the complexity of the RYR2 locus is high, with regions 22 
flanking the target site including repetitive elements (LINE, SINE, Alu). Another parameter that could 23 
influence targeting efficiency is the cell line used. Out of necessity we used different hPSC lines because of 24 
their starting genotype, which in some cases was disease- or patient-specific. Many similarities and 25 
differences have been reported between hPSC lines [16]. In our report, we found that the puromycin 26 
concentration required during selection varied from 0.25 to 7.5 μg/mL). Thus, it would be unsurprising if 27 
variation extended to differential targeting efficiencies between hPSC lines.  28 
Vector construction and lengths of homology regions are also factors known to impact targeted 29 
recombination [42]. The same design principles were used for all 4 loci but the distances between the PAM 30 
site in the gRNA and polymorphism (termed PAM-SNP) varied out of necessity. Differences in targeting 31 
frequency may be explained by the mechanism of repair. DNA repair occurs via multiple pathways or sub-32 
pathways including DNA double-strand break repair (DSBR), Holliday junction dissolution, synthesis-33 
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dependent strand annealing (SDSA) and single-strand DNA incorporation (ssDI) [43,44]. With regards DSBR, 1 
long conversion tracts (approx. ±1 kb) are generated either side of the of conversion zone, with probability 2 
of conversion decreasing as a function of PAM-SNP distance [45]. Linear dependency also occurs with 3 
ssODNs [9,43], but creates conversion tracts of approx. ±60 nucleotides [43], which is why this approach 4 
tends to only incorporate small insertions or substitutions.  5 
The PAM-SNP frequency-distance relationship may explain some of the differences in nature and 6 
efficiency of targeting events. For ACTC1, with a 300 nucleotide distance, there was a higher probability of 7 
recombination occurring between PAM site and polymorphism. After transposase-mediated cassette 8 
excision, the sequence in the final chromatogram would appear as untargeted because the approach was 9 
designed to be footprint-free. This may have contributed to a profile of clones being untargeted = high 10 
(25%), mono-allelic targeted = high (67%) and bi-allelic targeted = low (0%). In contrast, the short PAM-SNP 11 
distance of around 100 nucleotides or less for ADRB2 and GRK5 presented profiles of 0%, 8%, 33% and 8%, 12 
13%, 47% respectively. Fortuitously, only heterozygote mutations occur in humans for ACTC1, presumably 13 
because it would likely lead to early lethality, which is the case in mouse knockouts. However, the PAM-SNP 14 
distance is clearly not the only factor, since most (92%) clones for RYR2 were not targeted. We cannot be 15 
sure whether the one RYR2 clone was mono- or bi-allelic allelic targeting event since the template was 16 
identical to the healthy allele so only correction of the mutant allele could be detected. 17 
Our main goal in this work was to reduce the duration required to produce isogenic sets of hPSCs, 18 
with a specific emphasis on in vitro disease modelling of the cardiovascular system. While others have used 19 
the PiggyBac system, we describe an abbreviated version that not only saves time and effort but the 20 
number of population doublings required to produce the gene edited cells. This is important because both 21 
empirical experimentation [14] and mathematical modelling [46] shows that genetic and epigenetic change 22 
are inevitable as a function of time.  23 
The targeted clones in this study were examined by karyotyping of at least 30 metaphase spreads. 24 
Nevertheless, further detailed analysis will be need to examine the broader stability of these lines. The rate 25 
of epigenetic change is highest soon after hESC line derivation, with most changes being haphazard [14,15]. 26 
In contrast, many genetic changes are predictable. This is exemplified by a large-scale study [14] of 136 27 
hESC and hiPSC lines from 38 laboratories worldwide, which showed a progressive tendency to acquire 28 
changes on prolonged culture. Common changes at the chromosome level were part or whole gains of 1, 12 29 
and/or 17. However, in approximately 20% of lines studied, there was also gain of a minimal amplicon in 30 
chromosome 20q11.21. This included three genes, ID1, BCL2L1 and HM13, with BCL2L1 driving a selective 31 
advantage for hPSC survival in culture. Whether stochastic or non-stochastic, these changes may affect the 32 
quality of the cells for biomedical application. Strategies to reduce the population doublings required 33 
during their manipulation should be welcomed, though to date this has not been considered. This would 34 
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bring genetically engineered hPSCs into kilter with the international guidelines for clinical grade lines, 1 
where low passage seed stocks or master banks are recommended [47].  2 
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Figure Legends 
Figure 1. PiggyBac targeting at the ADRB2 locus. Panel (A) shows a schematic of the ADRB2 locus structure 
before targeting, after insertion of the PiggyBac positive-negative selection cassette and after cassette 
excision. The black (G/G) and red (A/C) vertical lines indicate the location of the polymorphic changes 
induced at bases 46 and 79. Primer locations (b1, b2) for genotyping are indicated, along with PCR product 
sizes. β2-L and β2-R indicate the left and right regions of homology, each of 1kb in length; TV, targeting 
vector; PB, PiggyBac; PGK, phosphoglycerate kinase promoter; PURO, puromycin-N-acetyltransferase; TK, 
thymidine kinase. Panel (B) shows the time line of the conventional two step PiggyBac targeting approach 
(upper) and the simplified approach (lower). In (C), expression of the ADRB2 gene was evaluated by 
quantitative realtime PCR in undifferentiated hPSCs (U) and through a 66 day timecourse of directed 
monolayer differentiation to cardiomyocytes; beating sheets appeared from between d8-12. Data are 
mean±SEM; n=4. 
 
Figure 2. Polymorphic changes to the ADRB2 locus in hPSCs. The nucleotide and translated single letter 
amino acid sequences are shown for the 5’ region of the ADRB2 locus. The targeting strategy introduces 
changes at positions 46 and 79 (non-synonymous in the peptide), and 124 and 126 (synonymous in the 
peptide) as indicated. Features identified are the location of the gRNA underlined, with PAM site boxed, 
and TTAA PiggyBac cassette insertion site.   
 
Figure 3. Gene editing at the ADRB2 locus in hPSCs. Panel (A) shows representative chromatogram 
synopses flanking positions 46, 79 and 124-126 of untargeted, mono- and bi-allelic targeting, and indels. A 
complete set for step 1 and step 2 targeting is in Supp Figs. 2A and 2B. The table in (B) summarises the 
different targeting events identified after step 1 (midpoint; after puromycin selection for clones containing 
the positive-negative selection cassette) and step 2 (after ganciclovir selection for clones in which the 
cassette has been excised). In panel (C), high risk off target (OT) sites were classified as known coding or 
regulatory sequences where gRNAs had full PAM site complementarity and/or fewer than 5 mismatches 
with the target. PCR genotyping showed no evidence for off target events. In (D), random integration was 
tested. The schematic shows the stages of targeting and location of PCRed regions. ADRB2 is a control for 
genomic DNA, whilst ADBR2-PT and TK test for the presence of the targeting cassette; results are shown in 
the gel images. Since no product was identified for AMP within the pBlueScript backbone, qPCR was used 
and compared against a positive control (pos) comprising plasmid DNA diluted to the equivalent of single 
copy gene level in HUES7 parental DNA. Housekeeping gene was 18S, n=3±SD; **** P<0.001, Dunnett’s 
test.    
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Figure 4. Polymorphic changes to the GRK5, ACTC1 and RYR2 loci in hPSCs. The nucleotide and translated 
single letter amino acid sequences are shown for each locus. The targeting strategy introduces non-
synonymous changes as indicated. In each case, the gRNA, with PAM site boxed, spans an endogenous 
TTAA cassette insertion site, which eliminates the need for changes to spare the targeting vector from 
Cas9-mediated cleavage. 
 
Figure 5. Gene editing at the GRK5, ACTC1 and RYR2 loci in hPSCs. The schematics in panel (A) show the 
loci for each gene before and after editing, with damaging (black to red; ACTC1), protective (red to black; 
GRK5) or rescue (red to black; RYR2) polymorphisms introduced. L and R represent the left and right regions 
of homology, while primer locations for g, a and r are indicated (full details in Supp. Table 1). TV, targeting 
vector. In (B), semi-quantitative RT-PCRs were carried out for each gene in undifferentiated hPSCs (Un) and 
cardiomyocytes at day 30 of differentiation (CM). Bands were quantified by densitometry and normalised 
to β-actin (ACTB) as a house keeping gene. M, marker; n=2, errors are ± SD. Panel (C) shows representative 
chromatogram synopses flanking polymorphic positions for each gene, while editing efficiencies are 
displayed in the tables in (D). Note that for RYR2, it is not possible to tell whether the event was mono- or 
bi-allelic, hence the ?? symbols.  
 
Figure 6. Retention of pluripotency characteristics in the edited hPSC lines. Panels (A-C) shows assessment 
of pluripotency characteristics in undifferentiated cells from each of the edited line. This included (A) 
immunostaining for the transcription factor, OCT4 (green; inset with DAPI [blue] counterstaining), (B) flow 
cytometry for TRA-1-81 (blue), SSEA4 (green) and SSEA1 (red), relative to unstained (purple), and (C) G-
banding karyotyping of 30 metaphase spreads per line, with a representative karyogram shown for each. In 
panel (D), directed monolayer differentiation produced cardiomyocytes of >88% purity, as gauged by 
immunostaining for α-actinin (red) relative to total nuclei count (DAPI, blue). Scale bar is 100µm; n = 2-4, 
SD.  
 
Figure 7. Functional effects of chronic isoprenaline on GRK5-L41 and –Q41 hPSC-CMs. Using the 
CardioExcyte impedance platform, the beat rate of the edited hPSC-CM lines was monitored at ~10 minute 
intervals during chronic stimulation (~50 h) with 100nM isoprenaline (Iso; Ai, Aii) with or without beta-
blockade with 200nM propranolol (Prop; Bi, Bii). Data were binned for the periods shown and plotted as 
normalised to percent change from BL (baseline). The response ratios were calculated by dividing each 
datum from GRK5-Q41 by the corresponding time point from GRK5-L41 hPSC-CMs without (Aiii) or with 
(Biii) blockade with propranolol. Arrow head indicates where there is a highly significant decline in the beat 
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rate of the GRK5-Q41 hPSC-CMs. Dunnett’s test relative to BL: * P<0.05; ** P<0.01; *** P<0.001; **** 
P<0.0001. 
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ATG GGG CAA CCC GGG AAC GGC AGC GCC TTC TTG CTG  
 M   G   Q   P   G   N   G   S   A   F   L   L 
            A 
 
GCA CCC AAT GGA AGC CAT GCG CCG GAC CAC GAC GTC  
 A   P   N   G   S   H   A   P   D   H   D   V 
        C     
 
ACG CAG GAA AGG GAC GAG GTG TGG GTG GTG GGC ATG 
 T   Q   E   R   D   E   V   W   V   V   G   M 
                    T A 
 
GGC ATC GTC ATG TCT CTC ATC GTC CTG GCC ATC GTG  
 G   I   V   M   S   L   I   V   L   A   I   V 
PAM site 
Creation of TTAA excision site (c.C124T; c.C126A) 
c.G79C: Glu to Gln conversion at position 27 
Cassette insertion site 
c.G46A: Gly to Arg conversion at position 16 
ADRB2 (b2 adrenoceptor) 
Figure 2 
Start codon 
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Endogenous  
locus 
Edited  
locus 
ACTC1 
ACTC1-L ACTC1-R 
301G 
gRNA/Cas9/TV 
a1 a2 
TTAA 
ACTC1-L ACTC1-R 
301A 
GRK5 
GRK5-L GRK5-R 
122A 
gRNA/Cas9/TV  Transposase 
g1 g2 
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122T 
RYR2 
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6737T 
gRNA/Cas9/TV 
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6737C 
Untargeted ACTC1301G/G  25% (3 of 12) 
Mono-allelic ACTC1301A/G  66.6% (8 of 12) 
Bi-allelic ACTC1301A/A  0% (0 of 12) 
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Figure 5 
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Figure 6 
GRK5 ACTC1 RYR2 
A) Pluripotent markers 
       (Immunostaining) 
C) Karyogram 
D) Cardiomyocyte 
        differentiation 
B) Pluripotent markers 
       (Flow cytometry) 
ADRB2 
a-actinin: 89 ± 3 % 
OCT4 = 96 ± 2% OCT4 = 99 ±  1% 
a-actinin: 88 ±  2% 
OCT4 = 99 ±  1% OCT4 = 99.69±0.67% OCT4 = 99 ± 1% 
a-actinin: 98.78±0.15% 
1 2 3 4 5 
6 7 8 9 10 11 12 
13 14 15 16 17 18 
19 20 21 22 X Y 
a-actinin: 94.45±3.35% 
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Simplified footprint-free Cas9/CRISPR editing of cardiac-associated genes in human pluripotent stem cells 1 
 2 
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 1 
 2 
 3 
Supp Figure 1. Optimisation of transfection conditions for gene editing in hPSCs. Transfection efficiency of a 4 
GFP-expressing plasmid into undifferentiated HUES7 hESC was evaluated using chemical transfection with Fugene 5 
HD or using various programmes embedded in the Amaxa 4D nucleofection system. Shown are representative 6 
fields of GFP (green; inset is with DAPI [blue]), which were quantified by high content image analysis using the 7 
Operetta confocal plate reader. Data are n=3, mean ± SEM. Scale bar is 100µm.  8 
 9 
10 
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 1 
 2 
Supp Figures 2A and 2B. Sequencing data for ADRB2 editing. Chromatograms derived from direct sequencing of 3 
PCR products are shown for the clones picked after step 1 (Figure 2A; midpoint; after puromycin selection) and 4 
after step 2 (Figure 2B; end; after ganciclovir selection and cassette excision). In 2A (read in forward direction), 5 
the polymorphic sites at nucleotide positions 46 and 79 are shown, but not the TTAA site since this is disrupted by 6 
cassette insertion. In 2B (read in reverse direction), the polymorphic sites at nucleotide positions 46 and 79, as 7 
well as the reconstituted TTAA site. Heterozygote (mono-allelic) and homozygote (bi-allelic) targeting events are 8 
shown, with the former indicated by double peaks and both bases shown. Arrows indicate region where sequence 9 
becomes misaligned due to indels. 10 
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 1 
 2 
Supp Figures 2A and 2B. Sequencing data for ADRB2 editing. Chromatograms derived from direct sequencing of PCR products are shown for the clones picked after step 3 
1 (Figure 2A; midpoint; after puromycin selection) and after step 2 (Figure 2B; end; after ganciclovir selection and cassette excision). In 2A (read in forward direction), the 4 
polymorphic sites at nucleotide positions 46 and 79 are shown, but not the TTAA site since this is disrupted by cassette insertion. In 2B (read in reverse direction), the 5 
polymorphic sites at nucleotide positions 46 and 79, as well as the reconstituted TTAA site. Heterozygote (mono-allelic) and homozygote (bi-allelic) targeting events are 6 
shown, with the former indicated by double peaks and both bases shown. Arrows indicate region where sequence becomes misaligned due to indels. 7 
8 
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 1 
 2 
Supp Figure 3. Gene editing in the MYH7 locus (β-myosin heavy chain). Panel (A) shows RT-PCR analysis of MYH7 in different samples of hPSC lines in undifferentiated 3 
state (U1-U4) or after directed monolayer differentiation to cardiomyocytes (CM1-CM4); only the latter show expression. MW, molecular weight marker; NTC, no 4 
template control; G, genomic DNA. Despite the lack of gene expression in the undifferentiated hPSCs, panel (B) shows the targeting efficiencies of ~25% after insertion of 5 
a selection cassette flanked by FRT recombination sites. In (C), note that by RT-PCR MYH7 expression occurs in wildtype (WT) cells or targeted cells from which the 6 
selection cassette has been removed with FLP recombinase (excised) but not when the selection cassette is present (cassette), even though it is positioned in an intron 7 
away from any annotated elements or splice junctions. MW, molecular weight marker.  8 
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Supp Table 1. Primers for vector construction and genotyping. LH, left homology; RH, right homology; VC, vector construction; CA, cassette amplification 1 
 2 
Target Accession  Reagent Use Forward / reverse 5’  3’ sequence Product size (bp) See Fig. 
ADRB2 
NM_000024  
LH primer 
VC 
F GGTCGACGGTATCGATAAGCTTGATTTCGGAGTACCCAGATGGAGAC 
1084 
Fig. 1A 
R ACGCAGACTATCTTTCTAGGGTTAAAGACATGACGATGCCCATGC 
RH primer 
F CAATATGATTATCTTTCTAGGGTTAATCGTCCTGGCCATCGTGTTTGG 
1083 
R ATCCCCCGGGCTGCAGGAATTCGATAGTCTTCCGTGCCTGGGAGGTC 
ADRB2puroΔtk 
CA 
F CATCGTCATGTCTTTAACCCTAGAAAGATAGTCTGCG 
3267 
puroΔtkADRB2 R ACACGATGGCCAGGACGATTAACCCTAGAAAGATAATCATATTGTGACG 
Primer b1 
Genotyping 
F GCTCGGGTGAGGCAAGTTCGG 
1331  
Primer b2 R ATGGCAAAGTAGCGATCCAC 
Primer b3 
Expression 
F GCTGAGTGTGCAGGACGAGT 
555 Fig. 5 
Primer b4 R ATGGCAAAGTAGCGATCCAC 
gRNA Targeting + Strand GCCGGACCACGACGTCACGC n.a. Fig. 2 
NM_198179 Primer OT1 OT1 
F CCTGAGCTGCTCTCCTTTCC 
378 
Fig. 3C 
R CCAGAGCATTGCCAAAGAGC 
NM_002570  Primer OT2 OT2 
F CAGCATGGAGAAGAGGAGCC 
387 
R ACTGTCACCCTTGTCCCAGA 
NM_138384  Primer OT3 OT3 
F GATGCCATCATGGAGCCTCT 
357 
R ACCCTAGTGACCAGCATGGA 
NM_014668 Primer OT4 OT4 
F TGCACTCAATGAGCAAGGCT 
344 
R CCCAGCTGGACCAGGTAGTA 
NM_033405 Primer OT5 OT5 
F GAGGAGGTGATCAGGCAGC 
332 
R TCCCCATGCTTCTCACACAG 
NM_000024 ADRB2 
Random 
integration 
F GCTGAGTGTGCAGGACGAGT 
554 
Fig. 3D 
R ATGGCAAAGTAGCGATCCAC 
n/a 
ADRB2-PT 
F GCTGAGTGTGCAGGACGAGT 
371 
R CTAAATGCACAGCGACGGATTCGCGC 
TK 
F ATAGACGGTCCTCACGGGAT 
269 
R ATATGAGGAGCCAGAACGGC 
AMP 
F CTGCAATGATACCGCGAGAC 
576 
R TCCTTGAGAGTTTTCGCCCC 
GRK5 
NM_005308 
LH primer 
VC 
F GGTCGACGGTATCGATAAGCTTGATTAAGCGCCACTGTAAGGGTGGAGAG 
1156 
Fig. 5 
R ACGCAGACTATCTTTCTAGGGTTAATGCACAAACGGCTTGGCGGATCACC 
RH primer 
F CAATATGATTATCTTTCTAGGGTTAAGGCAAATGGGTGAGCCGCCAAGCTG 
1146 
R AGTGGATCCCCCGGGCTGCAGGAATTCGATGGCACAGATGGCCTCCTATC 
Primer g1 
Genotyping 
F CAGAGCAAGGTGGAGGACAG 
1446 
Primer g2 R GATAGGAGGCCATCTGTGCC 
 Primer g3 
Expression 
F TCCGAAGGACCATAGACAGAGA  
403 
 Primer g4 R TGCCTTTCCAACCACTTCCA 
WGE ID: 1075072174  gRNA 2a 
Targeting 
- Strand TTTGTGCATTAAGGCAAATG 
n.a. Fig. 4 
 WGE ID: 1075072180 gRNA 2b + Strand GTGAGGCAAATGCCAATCAG 
ACTC1 NM_005159 
LH primer 
VC 
F GGTCGACGGTATCGATAAGCTTGATGCCAGACAGGCTGCCAAGCAGG 
1050 
Fig. 5 R ACGCAGACTATCTTTCTAGGGTTAACTCTTTCTCTTAGCACAGAC 
RH primer F CAATATGATTATCTTTCTAGGGTTAACAGTAGTGCCCTGAGGTTAGTTT 1051 
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R ATCCCCCGGGCTGCAGGAATTCGATGCTGGAAGAGTGTCTCAGGACAG 
Primer a1 
Genotyping 
F CACCTGACCCTCTTGTTCGA 
2267 
Primer a2 R GCGGATTCAGTGAGAGAGGA 
Primer a3 
Expression 
F GGTGATGAAGCCCAGAGCAA  
461 
Primer a4 R GTGGTGACAAAGGAGTAGCC 
gRNA Targeting + Strand GAGTTAACAGTAGTGCCCTG n.a. Fig. 4 
RYR2 NG_008799.2 
LH primer 
VC 
F ACGGTATCGATAAGCTTGATTACGTAAAATTAAACTTTAA 
360 
Fig. 5 
R GACTATCTTTCTAGGGTTAAAATATTGAGAAAACCGTGAA 
RH primer 
F TGATTATCTTTCTAGGGTTAATATAAGTAAGGTTGGTGCA 
1041 
R CCGGGCTGCAGGAATTCGATCAGTAAAGGAAACAGGAAGA 
Primer r1 
Genotyping 
F CCCCAGCTATGAGAGGTTCA 
445 
Primer r2 R GAACGTTGGTTCTCCTTCCA 
Primer r3 
Expression 
F TGCATGAAAGCATCAAACGCA  
560 
Primer r4 R TGAGTAGAGCCGGAGAGTGT 
gRNA Targeting + Strand ATTTTAAATATAAGTAAGGT n.a. Fig. 4 
ACTB NM_001101.3 
Primer GAP1 Expression F CAAGAGATGGCCACGGCT  
312 Fig. 5 
Primer GAP2  R CTTGATCTTCATTGTGCTGGG 
 1 
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